A comparative,prospective, nationwide study of Inflectra (biosimilar monoclonal antibody) and Remicade for inducing and maintaining remission in inflammatory bowel disease (IBD), Crohn's disease (CD) and ulcerative colitis (UC) in Hungarian patients.

Trial Profile

A comparative,prospective, nationwide study of Inflectra (biosimilar monoclonal antibody) and Remicade for inducing and maintaining remission in inflammatory bowel disease (IBD), Crohn's disease (CD) and ulcerative colitis (UC) in Hungarian patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Hospira
  • Most Recent Events

    • 01 Nov 2017 Final results from a prospective nationwide inflammatory bowel disease cohort presented at the 25th United European Gastroenterology Week
    • 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week
    • 19 Oct 2016 Results (n= 291) presented at the 24th United European Gastroenterology Week
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top